Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rujiexiao is a Traditional Chinese Medicine (TCM) preparation developed by Jinan Central Hospital Affiliated to Shandong First Medical University for the external treatment of breast-related conditions. It is primarily indicated for the management of breast nodules and breast hyperplasia (mammary dysplasia), particularly those associated with emotional stimulation or liver qi stagnation according to TCM theory. The preparation is designed for topical application (external treatment) to evaluate its clinical efficacy in reducing nodule size and alleviating symptoms such as breast pain. Clinical research has focused on its role in individualized prevention and treatment strategies for patients with specific personality characteristics and temperament types.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Rujiexiao (Central Hospital Affiliated to Shandong First Medical University).